[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100388350":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":35,"responsibleParty":53,"collaborators":29,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":29,"enrollmentInfo":64,"targetDuration":29,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":29,"overallStatus":37,"whyStopped":29,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Washington University School of Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Continuous patch monitoring system","EXPERIMENTAL","-Participants will receive standard of care treatment with either arsenic trioxide, ribociclib, or capecitabine. They will have continuous patch monitor system (BodyGuardian Mini Plus) applied on or prior to the first day of therapy and will receive at least 5 ECGs for comparison during the first 30 days of treatment.",[13],"Device: BodyGuardian Mini Plus",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","BodyGuardian Mini Plus","The BodyGuardian Mini Plus attaches to the upper chest of the patient through the use of an adhesive patch. ECG tracings are recorded continuously and sent to the linked smartphone and subsequently to a cloud server.",[9],[9],[22],{"name":23,"affiliation":5,"role":24},"Joshua D Mitchell, M.D., FACC","PRINCIPAL_INVESTIGATOR",[26,31],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","314-494-3124",null,"jdmitchell@wustl.edu",{"name":32,"role":27,"phone":33,"phoneExt":29,"email":34},"Kaitlin Moore","314-273-0830","kaitlin.m.moore@wustl.edu",[36],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","St Louis","Missouri","63110","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-90.19789,38.62727,{"lat":47,"lon":46},[50,51,52],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},{"name":32,"role":27,"phone":33,"phoneExt":29,"email":34},{"name":23,"role":24,"phone":29,"phoneExt":29,"email":29},{"type":54,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100388350","continuous-versus-intermittent-cardiac-electrical-monitoring-100388350",false,"NCT04336644","Continuous Versus Intermittent cARdiac Electrical moNitorinG","CARING","Inclusion Criteria:\n\n* Diagnosis of acute promyelocytic leukemia (APL) and being initiated on standard of care arsenic trioxide OR Diagnosis of solid tumor and being initiated on standard of care capecitabine (alone or as part of combination treatment) OR Diagnosis of solid tumor and being initiated on standard of care ribociclib (alone or as part of combination treatment)\n* At least 18 years of age.\n* No allergy to adhesive patches.\n* Able to understand and willing to sign an IRB-approved written informed consent document.\n\nExclusion Criteria:\n\n* Younger than 18 years of age\n* Allergy to adhesive patches","ALL","18 Years",{"count":65,"type":66},60,"ESTIMATED","INTERVENTIONAL",[69],"NA","The purpose of this study is to validate the continuous patch monitoring system to evaluate cardiac arrhythmias in patients receiving drugs that can cause cardiac complications and compare the continuous patch system with standard electrocardiograms (ECGs).",[72,73],"Torsades de Pointe Caused by Drug","Long QT Syndrome","2025-12-28",{"date":76,"type":77},"2025-12-30","ACTUAL",{"date":79,"type":77},"2023-11-21",{"date":81,"type":66},"2026-12-31",{"name":5,"class":6},1]